Arrhythmia News and Research RSS Feed - Arrhythmia News and Research

An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
Arrhythmia patients who manage lifestyle factors more likely to have long-term survival

Arrhythmia patients who manage lifestyle factors more likely to have long-term survival

Patients suffering from the world's most common heart rhythm disorder can have their long-term outcomes significantly improved with an aggressive management of their underlying cardiac risk factors, according to University of Adelaide researchers. [More]
Daiichi Sankyo releases new formulation of LIXIANA 60 mg Tablets

Daiichi Sankyo releases new formulation of LIXIANA 60 mg Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)]. [More]
Study shows link between cardiac abnormalities, sudden unexpected death in epilepsy

Study shows link between cardiac abnormalities, sudden unexpected death in epilepsy

Groundbreaking findings describing the link between cardiac abnormalities and sudden unexpected death in epilepsy (SUDEP) will be presented at the American Epilepsy Society's Annual Meeting in December. [More]
Study on hospital alarm fatigue records more than 2.5 million alarms in one month

Study on hospital alarm fatigue records more than 2.5 million alarms in one month

Jessica Zègre-Hemsey, a cardiac monitoring expert at the University of North Carolina at Chapel Hill, and her colleagues at the University of California San Francisco, revealed more than 2.5 million alarms were triggered on bedside monitors in a single month - the first figure ever reported from a real-world hospital setting. [More]
Digoxin drug associated with higher risk of death, hospitalization among adults with atrial fibrillation

Digoxin drug associated with higher risk of death, hospitalization among adults with atrial fibrillation

Digoxin, a drug commonly used to treat heart conditions, was associated with a 71 percent higher risk of death and a 63 percent higher risk of hospitalization among adults with diagnosed atrial fibrillation and no evidence of heart failure, according to a Kaiser Permanente study that appears in the current online issue of Circulation: Arrhythmia and Electrophysiology. [More]
Findings illustrate need to monitor all races of heart failure patients for atrial fibrillation

Findings illustrate need to monitor all races of heart failure patients for atrial fibrillation

Black patients who have been diagnosed with heart failure are no less likely than white patients to get atrial fibrillation (an irregular heartbeat, or arrhythmia), according to a new study led by researchers in the Perelman School of Medicine at the University of Pennsylvania, which was presented today at the 2014 Scientific Sessions of the American Heart Association. [More]
Study reveals association between high burden of AFib and lower cognitive function

Study reveals association between high burden of AFib and lower cognitive function

iRhythm Technologies, Inc. announced today that study results presented during the American Heart Association Scientific Sessions showed an association between a high burden of atrial fibrillation (AFib) and lower cognitive function, specifically executive and verbal function. [More]
Cardiome Pharma announces results from Phase 3 clinical study of BRINAVESS

Cardiome Pharma announces results from Phase 3 clinical study of BRINAVESS

Cardiome Pharma Corp. today announced results from a Phase 3 clinical study conducted with BRINAVESS (vernakalant intravenous, RSD 1235) in the Asia-Pacific (A-P) region. [More]
FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily SAVAYSA (edoxaban) 60 mg dosing regimen for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF). [More]
University Medical Center's first atrial fibrillation unit opens in Germany

University Medical Center's first atrial fibrillation unit opens in Germany

Nearly 1.8 million people in Germany suffer from atrial fibrillation. This is the most common and clinically significant form of heart rhythm disorder. Shortness of breath, a sudden sense of dizziness, a feeling of pressure in the chest, and palpitations or thumping of the heart so extreme it can be felt beating rapidly and irregularly - this is how many patients describe their first episode of atrial fibrillation. [More]
QT Medical partners with LA BioMed to identify infants at risk of long QT syndrome

QT Medical partners with LA BioMed to identify infants at risk of long QT syndrome

Each year, some 2,000 babies are born in the U.S. with a genetic heart condition, known as long QT syndrome. If not diagnosed in time, babies with long QT syndrome can die from a sudden arrhythmia, or irregular heartbeat. [More]
French hospital uses Sophia DDM Platform to improve diagnostic testing of congenital disorders

French hospital uses Sophia DDM Platform to improve diagnostic testing of congenital disorders

The Hospices Civils de Lyon, the second-largest University Hospital Network in France, has elected to use the Sophia Genetics Data Driven Medicine (DDM) Platform to support improvements in diagnostic testing for patients suffering from congenital disorders. [More]
ECMO improves survival, neurological outcomes in patients suffering from cardiac arrest

ECMO improves survival, neurological outcomes in patients suffering from cardiac arrest

A new study shows that survival and neurological outcomes for patients in cardiac arrest can be improved by adding extracorporeal membrane oxygenation (ECMO) when performing cardiopulmonary resuscitation (CPR). [More]
High doses of fish oil supplements do not reduce atrial fibrillation

High doses of fish oil supplements do not reduce atrial fibrillation

High doses of fish oil supplements, rich in omega-3 fatty acids, do not reduce atrial fibrillation, a common type of irregular heartbeat in which the heart can beat as fast as 150 beats a minute. The results of the AFFORD trial led by the Montreal Heart Institute were published in the Journal of the American College of Cardiology on October 7th. [More]
Power grid failure inside injured cardiac cells triggers post-heart attack arrhythmias

Power grid failure inside injured cardiac cells triggers post-heart attack arrhythmias

Heart attack survivors often experience dangerous heart rhythm disturbances during treatment designed to restore blood flow to the injured heart muscle, a common and confounding complication of an otherwise lifesaving intervention. [More]
Cardiac arrhythmias pose risk in pulmonary hypertension patients

Cardiac arrhythmias pose risk in pulmonary hypertension patients

Supraventricular arrhythmias are common and usually cause clinical deterioration in patients with idiopathic pulmonary arterial hypertension, a study shows. [More]
Increasing prevalence of obstructive sleep apnea threatens public health and safety

Increasing prevalence of obstructive sleep apnea threatens public health and safety

Public health and safety are threatened by the increasing prevalence of obstructive sleep apnea, which now afflicts at least 25 million adults in the U.S., according to the National Healthy Sleep Awareness Project. Several new studies highlight the destructive nature of obstructive sleep apnea, a chronic disease that increases the risk of high blood pressure, heart disease, Type 2 diabetes, stroke and depression. [More]
New AliveECG app provides patients with free real-time AF detection in ECG recordings

New AliveECG app provides patients with free real-time AF detection in ECG recordings

AliveCor, Inc. announced today the launch of the latest version of the AliveECG app, which provides patients with free real-time atrial fibrillation (AF) detection in ECG recordings using its new FDA-cleared algorithm. [More]
RDT receives FDA clearance for Tempus Pro advanced medical monitor

RDT receives FDA clearance for Tempus Pro advanced medical monitor

RDT is pleased to announce that, following CE and other market approvals, it has received 510k clearance by the US Food and Drug Administration for the addition to the Tempus Pro medical monitor of: 12 Lead ECG recording interpretation, real-time arrhythmia detection, ST and QT monitoring and alarming (unique to a fully-featured pre-hospital transport monitor) an additional two channels of invasive blood pressure (four in total), Masimo rainbow SET co-oximetry, video laryngoscope and ultrasound. [More]
New evidence-based guidelines for prevention, treatment of POAF

New evidence-based guidelines for prevention, treatment of POAF

The American Association for Thoracic Surgery has released new evidence-based guidelines for the prevention and treatment of perioperative and postoperative atrial fibrillation (POAF) and flutter for thoracic surgical procedures. [More]